Nulisaseq ™ CNS Disease Panel 120 and Inflammation Panel 250 Support the discovery of biomarkers in 23,000 longitudinal samples
Alamar Biosciences, a company specializing in precision protomics, which enables early detection of diseases, announced strategic cooperation with the German Center for Neurodegenerative Diseases (DZNE) in order to have its highly sensitive Nulisaseq ™ CNS Disease Panel 120 and Inflammation Panel 250 in the Rhineland study-one of the world’s most comprehensive and most innovative longitudinal cuts-as well as to use in some of the clinical disease-specific cohorts of the Dzne. As part of this initiative, 23,000 plasma samples are profiled to speed up the discovery of biomarkers and to improve understanding of healthy aging and neurodegeneration.
“In order to understand aging and dementia, both modern technologies and well-characterized cohorts are necessary,” explains Prof. Monique Breteler, director of the population Health Sciences at the Dzne and senior test doctor of the Rhineland study. “The integration of Alamar’s multiplex panels into our research opens up new opportunities to decrypt the molecular signatures of brain age.”
The Dzne Rhineland study is an ongoing, large-scale population-based cohort to investigate the determinants of healthy aging and the development of neurodegenerative diseases over the entire lifespan. With the Nulisaseq CNS Disease Panel 120 from Alamar, researchers can measure hundreds of proteins that are connected to the brain, from minimal amounts of blood with exceptional sensitivity and specificity. In particular, the ability of the ZNS panel to distinguish in the plasma between the brain, phosphorylated dew and phosphorylated dew as a whole, is a groundbreaking progress for early detection and risk stratification of neurodegenerative diseases such as Alzheimer’s. Immune -related proteins that are involved in aging processes and neuroinflammation in connection with neurodegenerative diseases.
The resulting proteom data are connected to the extensive clinical, demographic and imaging data records of the study, so that the researchers pursue protein changes in time course, identify early biomarkers and support the development of precision diagnosis and targeted therapies.
“This partnership is a big step forward in retirement and dementia research,” explains Yuling Luo, PhD, founder, Chairman and CEO by Alamar Biosciences. “With the unique sensitivity of Nulisa and the depth of the Dzne Rheinland study, we can discover new protein biomarkers that show the course of cognitive health and the disease progression in aging populations.”
This collaboration reflects the joint efforts for scientific stringz, inclusivity and innovation in research on neurodegenerative diseases. By recording the various age courses in a comprehensive characterized population, Alamar and the Dzne want to advance earlier diagnoses, better forecasts and new therapeutic paths for age -related brain disorders.
Information on the Dzne Rhineland study
The Rhineland study of the Dzne (German Center for Neurodegenerative Diseases) is an ambitious, population-based cohort that traces thousands of people over decades to uncover the determinants of healthy aging and neurodegeneration. Detailed clinical, imaging, genetic and life -related data are collected and harmonized in order to provide more detailed insights into the aging brain. Find out more about the Dzne under www.dzne.de/en/and about the Dzne Rheinland study under www.rheinland-studie.de/en/.
Information on Alamar Biosciences, Inc.
Alamar Biosciences is a private bioscience company that has set itself the goal of promoting precision protomics to enable the earliest possible detection of diseases. The company’s own Nulisa Platform and the ARGO HT system seamlessly interlock with the latest progress in genomics in order to achieve a sensitivity to evidence in the single-digit Attomol area, which exceeds the most sensitive protein detection technology currently available on the market. You can find more information at alamarbio.com.
Photo: https://mma.prnewswire.com/media/2739794/German_Center_for_Neurogenerative_Diseases.jpg
Logo: https://mma.prnewswire.com/media/1810182/Alamar_Logo_WhiteOutline_RGB_4x1_Logo_V1.jpg
